company background image
INBX logo

Inhibrx NasdaqGM:INBX Stock Report

Last Price

US$34.11

Market Cap

US$1.8b

7D

-0.09%

1Y

38.7%

Updated

31 May, 2024

Data

Company Financials +

INBX Stock Overview

A clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates.

INBX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Inhibrx, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Inhibrx
Historical stock prices
Current Share PriceUS$34.11
52 Week HighUS$39.79
52 Week LowUS$14.31
Beta2.88
11 Month Change-0.55%
3 Month Change-6.42%
1 Year Change38.66%
33 Year Change55.97%
5 Year Changen/a
Change since IPO65.34%

Recent News & Updates

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Jun 07

Recent updates

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Jun 07

Is Inhibrx (NASDAQ:INBX) Using Debt Sensibly?

May 13
Is Inhibrx (NASDAQ:INBX) Using Debt Sensibly?

Inhibrx down 8% after announcing webcast for pathway for rare disease candidate

Oct 03

Inhibrx: Potential To Move To Registration Study With INBRX-101

Jun 10

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Mar 23
Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Shareholder Returns

INBXUS BiotechsUS Market
7D-0.09%-0.7%-1.6%
1Y38.7%19.8%30.8%

Return vs Industry: INBX exceeded the US Biotechs industry which returned 4.6% over the past year.

Return vs Market: INBX exceeded the US Market which returned 25.2% over the past year.

Price Volatility

Is INBX's price volatile compared to industry and market?
INBX volatility
INBX Average Weekly Movement1.4%
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: INBX has not had significant price volatility in the past 3 months.

Volatility Over Time: INBX's weekly volatility has decreased from 8% to 1% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009169Mark Lappeinhibrx.com

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company’s therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications.

Inhibrx, Inc. Fundamentals Summary

How do Inhibrx's earnings and revenue compare to its market cap?
INBX fundamental statistics
Market capUS$1.79b
Earnings (TTM)-US$271.15m
Revenue (TTM)US$1.78m

1,002x

P/S Ratio

-6.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INBX income statement (TTM)
RevenueUS$1.78m
Cost of RevenueUS$218.11m
Gross Profit-US$216.32m
Other ExpensesUS$54.83m
Earnings-US$271.15m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-5.17
Gross Margin-12,132.47%
Net Profit Margin-15,207.80%
Debt/Equity Ratio1,799.9%

How did INBX perform over the long term?

See historical performance and comparison